재발성/불응성 다발골수종 환자에서 Belantamab Mafodotin, Bortezomib 및 Dexamethasone과 Daratumumab, Bortezomib 및 Dexamethasone의 유효성 및 안전성 평가 (DREAMM 7)
DREAMM 7: Daratumumab, Bortezomib 및 Dexamethasone(D-Vd)의 조합과 비교하여 Belantamab Mafodotin, Bortezomib 및 Dexamethasone(B-Vd)의 조합의 효능 및 안전성을 평가하기 위한 다기관 공개 레이블 무작위 3상 연구 ) 재발성/불응성 다발성 골수종 환자
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
확장된 액세스
확장된 액세스
승인됨
- 사용 가능: 현재 이 연구 치료에 대해 확장된 액세스가 가능하며 임상 연구에 참여하지 않은 환자는 약물, 생물학적 제제 또는 의료 기기에 액세스할 수 있습니다. 연구 중입니다.
- 더 이상 사용할 수 없음: 이전에는 이 개입에 대해 확장된 액세스를 사용할 수 있었지만 현재 사용할 수 없으며 앞으로도 사용할 수 없습니다.
- 일시적으로 사용할 수 없음: 현재 이 개입에 대해 확장된 액세스를 사용할 수 없지만 향후 사용할 수 있을 것으로 예상됩니다.
- 마케팅 승인: 개입 대중이 사용할 수 있도록 미국 식품의약국(FDA)의 승인을 받았습니다.
연락처 및 위치
연구 장소
-
-
-
Athens, 그리스, 11528
- GSK Investigational Site
-
Thessaloniki, 그리스, 54007
- GSK Investigational Site
-
-
East Macedonia and Thrace
-
Alexandroupoli, East Macedonia and Thrace, 그리스, 681 00
- GSK Investigational Site
-
-
-
-
-
Groningen, 네덜란드, 9713 GZ
- GSK Investigational Site
-
-
South Holland
-
Dordrecht, South Holland, 네덜란드, 3318 AT
- GSK Investigational Site
-
-
-
-
-
Christchurch, 뉴질랜드, 8011
- GSK Investigational Site
-
Dunedin, 뉴질랜드, 9054
- GSK Investigational Site
-
Takapuna Auckland, 뉴질랜드, 1309
- GSK Investigational Site
-
Wellington, 뉴질랜드, 6021
- GSK Investigational Site
-
-
-
-
-
Pusan, 대한민국, 49241
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do, 대한민국, 13620
- GSK Investigational Site
-
Seoul, 대한민국, 06351
- GSK Investigational Site
-
Seoul, 대한민국, 06591
- GSK Investigational Site
-
Ulsan, 대한민국, 44033
- GSK Investigational Site
-
-
-
-
-
Cologne, 독일, 50937
- GSK Investigational Site
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, 독일, 89081
- GSK Investigational Site
-
-
Bavaria
-
München, Bavaria, 독일, 81377
- GSK Investigational Site
-
Würzburg, Bavaria, 독일, 97080
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, 독일, 40225
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, 독일, 07747
- GSK Investigational Site
-
-
-
-
-
Moscow, 러시아 제국, 125284
- GSK Investigational Site
-
Nizhny Novgorod, 러시아 제국, 603126
- GSK Investigational Site
-
Novosibirsk, 러시아 제국, 630087
- GSK Investigational Site
-
Saint Petersburg, 러시아 제국, 191024
- GSK Investigational Site
-
Saint Petersburg, 러시아 제국, 197 089
- GSK Investigational Site
-
Samara, 러시아 제국, 443021
- GSK Investigational Site
-
Saratov, 러시아 제국, 410028
- GSK Investigational Site
-
Ufa, 러시아 제국, 450083
- GSK Investigational Site
-
-
-
-
Arizona
-
Yuma, Arizona, 미국, 85364
- GSK Investigational Site
-
-
Kansas
-
Mission, Kansas, 미국, 66205-2005
- GSK Investigational Site
-
-
North Carolina
-
Denver, North Carolina, 미국, 80128
- GSK Investigational Site
-
-
Ohio
-
Blue Ash, Ohio, 미국, 45242-5665
- GSK Investigational Site
-
-
Texas
-
Tyler, Texas, 미국, 75702
- GSK Investigational Site
-
-
Virginia
-
Roanoke, Virginia, 미국, 24014
- GSK Investigational Site
-
-
-
-
-
Roeselare, 벨기에, 8800
- GSK Investigational Site
-
-
Brussels Capital
-
Jette, Brussels Capital, 벨기에, 1090
- GSK Investigational Site
-
Woluwé-Saint-Lambert, Brussels Capital, 벨기에, 1200
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, 벨기에, 9000
- GSK Investigational Site
-
-
-
-
-
Joinville, 브라질, 89201-260
- GSK Investigational Site
-
Natal, 브라질, 59075-740
- GSK Investigational Site
-
Rio de Janeiro, 브라질, 22775001
- GSK Investigational Site
-
São Paulo, 브라질, 04537-080
- GSK Investigational Site
-
São Paulo, 브라질, 05403-000
- GSK Investigational Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
- GSK Investigational Site
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, 브라질, 88020-210
- GSK Investigational Site
-
-
-
-
-
Barcelona, 스페인, 08035
- GSK Investigational Site
-
Barcelona, 스페인, 08916
- GSK Investigational Site
-
Cáceres, 스페인, 10003
- GSK Investigational Site
-
Gijón, 스페인, 33394
- GSK Investigational Site
-
L'Hospitalet de Llobrega, 스페인, 08908
- GSK Investigational Site
-
MOstoles Madrid, 스페인, 28933
- GSK Investigational Site
-
Madrid, 스페인, 28007
- GSK Investigational Site
-
Madrid, 스페인, 31008
- GSK Investigational Site
-
Murcia, 스페인, 30008
- GSK Investigational Site
-
PamplonaNavarra, 스페인, 31008
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, 스페인, 28223
- GSK Investigational Site
-
Salamanca, 스페인, 37007
- GSK Investigational Site
-
-
-
-
-
Bournemouth, 영국, BH7 7DW
- GSK Investigational Site
-
Cardiff, 영국, CF14 4XW
- GSK Investigational Site
-
Dundee, 영국, DD1 9SY
- GSK Investigational Site
-
Leicester, 영국, LE1 5WW
- GSK Investigational Site
-
London, 영국, W12 0NN
- GSK Investigational Site
-
Stoke-on-Trent, 영국, ST4 6QG
- GSK Investigational Site
-
Sutton, 영국, SM2 5PT
- GSK Investigational Site
-
-
-
-
-
Jerusalem, 이스라엘, 91120
- GSK Investigational Site
-
Kfar Saba, 이스라엘, 44281
- GSK Investigational Site
-
Ramat Gan, 이스라엘, 52621
- GSK Investigational Site
-
Tel Aviv, 이스라엘, 64239
- GSK Investigational Site
-
-
-
-
-
Bergamo, 이탈리아, 24127
- GSK Investigational Site
-
Bologna, 이탈리아, 40138
- GSK Investigational Site
-
Brescia, 이탈리아, 25123
- GSK Investigational Site
-
Catania, 이탈리아, 95123
- GSK Investigational Site
-
Meldola FC, 이탈리아, 47014
- GSK Investigational Site
-
Milan, 이탈리아, 20133
- GSK Investigational Site
-
Ravenna, 이탈리아, 48121
- GSK Investigational Site
-
Roma, 이탈리아, 00168
- GSK Investigational Site
-
Siena, 이탈리아, 53100
- GSK Investigational Site
-
Torino, 이탈리아, 10126
- GSK Investigational Site
-
-
-
-
-
Aichi, 일본, 467-8602
- GSK Investigational Site
-
Aichi, 일본, 441-8570
- GSK Investigational Site
-
Aomori, 일본, 030-8553
- GSK Investigational Site
-
Ehime, 일본, 790-8524
- GSK Investigational Site
-
Fukuoka, 일본, 806-8501
- GSK Investigational Site
-
Fukuoka, 일본, 807-8555
- GSK Investigational Site
-
Fukuoka, 일본, 810-8563
- GSK Investigational Site
-
Fukuoka, 일본, 815-8555
- GSK Investigational Site
-
Gifu, 일본, 503-8502
- GSK Investigational Site
-
Gunma, 일본, 377-0280
- GSK Investigational Site
-
Hyōgo, 일본, 670-8540
- GSK Investigational Site
-
Kanagawa, 일본, 247-8533
- GSK Investigational Site
-
Kanagawa, 일본, 221-0855
- GSK Investigational Site
-
Kochi, 일본, 781-8555
- GSK Investigational Site
-
Nagano, 일본, 392-8510
- GSK Investigational Site
-
Okayama, 일본, 701-1192
- GSK Investigational Site
-
Osaka, 일본, 545-8586
- GSK Investigational Site
-
Osaka, 일본, 530-0012
- GSK Investigational Site
-
Shizuoka, 일본, 411-8777
- GSK Investigational Site
-
-
-
-
-
Beijing, 중국, 100191
- GSK Investigational Site
-
Beijing, 중국, 100020
- GSK Investigational Site
-
Changchun, 중국, 130012
- GSK Investigational Site
-
Guangzhou, 중국, 510060
- GSK Investigational Site
-
Guangzhou, 중국, 510515
- GSK Investigational Site
-
Hangzhou, 중국, 310003
- GSK Investigational Site
-
Jinan, 중국, 250012
- GSK Investigational Site
-
Nanjing, 중국, 210008
- GSK Investigational Site
-
Shenyang, 중국, 110001
- GSK Investigational Site
-
Suzhou, 중국, 215006
- GSK Investigational Site
-
Tianjin, 중국, 300020
- GSK Investigational Site
-
Zhengzhou, 중국, 450052
- GSK Investigational Site
-
-
-
-
-
Brno, 체코, 625 00
- GSK Investigational Site
-
Hradec Králové, 체코, 500 05
- GSK Investigational Site
-
Ostrava, 체코, 708 52
- GSK Investigational Site
-
Prague, 체코, 128 08
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
London, Ontario, 캐나다, N6A 5W9
- GSK Investigational Site
-
Toronto, Ontario, 캐나다, M4N 3M5
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, 캐나다, H4J 1C5
- GSK Investigational Site
-
-
-
-
-
Chorzów, 폴란드, 41-500
- GSK Investigational Site
-
Krakow, 폴란드, 30510
- GSK Investigational Site
-
Lodz, 폴란드, 93-513
- GSK Investigational Site
-
Lublin, 폴란드, 20-081
- GSK Investigational Site
-
Lublin, 폴란드, 20-090
- GSK Investigational Site
-
Nowy Sącz, 폴란드, 33-300
- GSK Investigational Site
-
Poznan, 폴란드, 60-569
- GSK Investigational Site
-
Warsaw, 폴란드, 02-781
- GSK Investigational Site
-
-
-
-
-
Amiens, 프랑스, 80054
- GSK Investigational Site
-
Caen, 프랑스, 14033
- GSK Investigational Site
-
Nice, 프랑스, 06200
- GSK Investigational Site
-
Paris, 프랑스, 75651
- GSK Investigational Site
-
Rennes, 프랑스, 35033
- GSK Investigational Site
-
-
-
-
New South Wales
-
Camperdown, New South Wales, 호주, 2050
- GSK Investigational Site
-
Liverpool, New South Wales, 호주, 2170
- GSK Investigational Site
-
Newcastle, New South Wales, 호주, 2298
- GSK Investigational Site
-
St Leonards, New South Wales, 호주, 2065
- GSK Investigational Site
-
Wollongong, New South Wales, 호주, 2500
- GSK Investigational Site
-
-
Queensland
-
Benowa, Queensland, 호주, 4217
- GSK Investigational Site
-
Herston, Queensland, 호주, 4029
- GSK Investigational Site
-
-
South Australia
-
Ashford, South Australia, 호주, 5037
- GSK Investigational Site
-
-
Victoria
-
Box Hill, Victoria, 호주, 3128
- GSK Investigational Site
-
Heidelberg, Victoria, 호주, 3084
- GSK Investigational Site
-
Melbourne, Victoria, 호주, 3004
- GSK Investigational Site
-
-
Western Australia
-
Murdoch, Western Australia, 호주, 6150
- GSK Investigational Site
-
Nedlands, Western Australia, 호주, 6009
- GSK Investigational Site
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
-
Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Must have at least 1 aspect of measurable disease, defined as one of the following;
- Urine M-protein excretion >=200 mg per 24-hour, or
- Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
- Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
-
All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.
-
Adequate organ function
Exclusion Criteria:
- Intolerant to daratumumab.
- Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
- Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
- Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
- Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
- Prior allogenic stem cell transplant.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
- Corneal epithelial disease.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: 벨란타맙 마포도틴 및 보르테조밉 + 덱사메타손(A군)
|
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity |
|
활성 비교기: Daratumumab 및 Bortezomib + Dexamethasone(아암 B)
|
Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity Anti-cluster of differentiation 38 [CD-38] monoclonal antibody |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-free Survival (PFS)
기간: Up to approximately 41 months
|
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis. |
Up to approximately 41 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
안과 검진에서 안구 이상 소견을 보인 참가자 수
기간: 최대 73개월
|
최대 73개월
|
|
|
Complete Response Rate (CRR)
기간: Up to 73 months
|
CRR is defined as percentage of participants with a confirmed complete response or better. |
Up to 73 months
|
|
Overall Response Rate (ORR)
기간: Up to 73 months
|
ORR is defined as percentage of participants with a confirmed partial response or better. |
Up to 73 months
|
|
Clinical Benefit Rate (CBR)
기간: Up to 73 months
|
CBR is defined as percentage of participants with a confirmed minimal response (MR) or better |
Up to 73 months
|
|
Duration of Response (DoR)
기간: Up to 73 months
|
DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first. |
Up to 73 months
|
|
Time to Response (TTR)
기간: Up to 73 months
|
TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better. |
Up to 73 months
|
|
Time to Progression (TTP)
기간: Up to 73 months
|
TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first. |
Up to 73 months
|
|
Overall Survival (OS)
기간: Up to 73 months
|
OS is defined as time from the date of randomization until the date of death due to any cause. |
Up to 73 months
|
|
Progression-free Survival on Subsequent Line of Therapy (PFS2)
기간: Up to 73 months
|
Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier. |
Up to 73 months
|
|
Minimal Residual Disease (MRD) Negativity Rate
기간: Up to 73 months
|
Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS). |
Up to 73 months
|
|
Number of Participants With Adverse Events (AEs)
기간: Up to 73 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Hematology Parameters
기간: Up to 73 months
|
Blood samples will be collected for the analysis of hematology parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Clinical Chemistry
기간: Up to 73 months
|
Blood samples will be collected for the analysis of clinical chemistry parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Urine Dipstick
기간: Up to 73 months
|
Urine samples will be collected for the urine dipstick analysis. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
기간: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
기간: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
기간: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
기간: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers. |
Up to 73 months
|
|
Titers of ADAs Against Belantamab Mafodotin
기간: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers. |
Up to 73 months
|
|
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
기간: Up to 73 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to 73 months
|
|
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
기간: Up to 73 months
|
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
Up to 73 months
|
|
Change From Baseline in HRQoL as Measured by EORTC IL52
기간: Up to 73 months
|
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning. |
Up to 73 months
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: GSK Clinical Trials, GlaxoSmithKline
간행물 및 유용한 링크
일반 간행물
- Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15.
- Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
- Zhang X, Xing X, Wang Z, Wang K, Hua Y, Zhang L, Dong X. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2026 Sep 11. doi: 10.1007/s41669-026-00681-8. Online ahead of print.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 혈관 질환
- 심혈관 질환
- 신생물
- 면역계 질환
- 조직학적 유형에 따른 신생물
- 혈액 질환
- 림프 증식 장애
- 면역증식성 장애
- 신생물, 형질세포
- 지혈 장애
- 파라단백혈증
- 혈액 단백질 장애
- 출혈성 장애
- 헴 및 림프병
- 다발성 골수종
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- 다 환식 화합물
- 무기 화학 물질
- Pretadienes
- 임신
- 스테로이드
- 융합 링 화합물
- 스테로이드, 불소
- Pregnadienetriols
- 보 론산
- 산, 비 카르 복실
- 산
- 붕소 화합물
- 피라진
- 보르테조밉
- 덱사메타손
- 다라 토무 맙
- Belantamab Mafodotin
기타 연구 ID 번호
기타 연구 ID 번호
- 207503
- 2018 (미국 NIH 보조금/계약)
- 2018-003993-29 (레지스트리 식별자: EudraCT (EU))
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .